Industry Research Reports
Home > Reports > Consumer Goods > HMO Infant Formula- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
HMO Infant Formula- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
Industry: Consumer Goods
Published Date: 2026-01-05
Pages: 107 Pages
Report ld: 5514036
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
HMO Infant Formula Market Size(US$)
CAGR 2026-2032
10.8%
Market Size,2032
USD 8,615
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 4,649 million
Market Forecast in 2032(Value)
US$ 8,615 million
CAGR
10.8%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global market for HMO Infant Formula was estimated to be worth US$ 4236 million in 2025 and is projected to reach US$ 8615 million, growing at a CAGR of 10.8% from 2026 to 2032.
The potential shifts in the 2025 U.S. tariff framework pose substantial volatility risks to global markets. This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on HMO Infant Formula cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Human milk oligosaccharides (HMOs) are the third most abundant component in breast milk and one of the most important components in breast milk. It is precisely because of the existence of HMOs that breastfeeding has become the gold standard for infant nutrition. The latest research shows that HMOs can effectively enhance the benefits of breastfeeding, such as strengthening the immune system and promoting healthy brain development. In addition, HMOs can promote intestinal development, improve intestinal resilience, and promote the balance of intestinal microbiota. HMO is particularly important in improving the health and nutritional needs of infants and young children. Since infant formula is mainly made from cow and goat milk, and the content of HMO in cow and goat milk is very low, adding HMO to infant formula is more in line with breast milk nutrition and can better protect the healthy growth of babies.
Global key players of HMO Infant Formula include Nestlé (Wyeth Nutrition), Danone (Aptamil), FrieslandCampina (Friso), Abbott, Mead Johnson(Reckitt), etc. The top five players hold a share about 94%. Americas is the world's largest market for HMO Infant Formula and holds a share about 58%, followed by Europe and Asia-Pacific, with share about 28% and 13%, separately. In terms of product type, 2'-FL is the largest segment, accounting for a share about 96%. In terms of application, Online Channel is the largest field with a share about 33 percent.
This report provides a comprehensive view of the global market for HMO Infant Formula, covering total sales volume, sales revenue, pricing, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Sales Channel.
The HMO Infant Formula market size, estimations, and forecasts are presented in terms of sales volume (Tons) and revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding HMO Infant Formula.
MARKET SEGMENTATION
By Company
- Abbott
- Mead Johnson（Reckitt）
- Nestlé（Wyeth Nutrition）
- Danone (Aptamil)
- FrieslandCampina (Friso)
- Biostime
- Yili Group (Ausnutria Dairy)
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- 2'-Fucosyllactose (2'-FL)
- Others
Segment by Application
- Online Channel
- Specialty Store
- Supermarket
- Others
CHAPTER OUTLINE
Chapter 1: Introduces the scope of the report and the global market size (value, volume, and price). It also summarizes market dynamics and Recent Developments; identifies key drivers and restraints; outlines challenges and risks for manufacturers; reviews relevant industry policies and U.S. tariff implications.
Chapter 2: Provides a detailed analysis of the HMO Infant Formula manufacturers' competitive landscape—including pricing, sales and revenue shares, Recent Developments plans, and mergers and acquisitions (M&A).
Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 4: Analyzes market segmentation by Sales Channel, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 5: Presents HMO Infant Formula sales and revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.
Chapter 6: Presents HMO Infant Formula sales and revenue at the country level. It provides segmented data by Type and by Sales Channel for each country/region.
Chapter 7: Profiles key players, detailing the main companies' product sales, revenue, pricing, gross margin, product portfolios, Recent Developments, etc.
Chapter 8: Analyzes the industry value chain, including upstream suppliers and downstream applications/customers.
Chapter 9: Conclusion.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Market Overview
1.1 HMO Infant Formula Product Introduction
1.2 Global HMO Infant Formula Market Size Forecast
1.2.1 Global HMO Infant Formula Sales Value (2021–2032)
1.2.2 Global HMO Infant Formula Sales Volume (2021–2032)
1.2.3 Global HMO Infant Formula Sales Price (2021–2032)
1.3 HMO Infant Formula Market Trends & Drivers
1.3.1 HMO Infant Formula Industry Trends
1.3.2 HMO Infant Formula Market Drivers & Opportunities
1.3.3 HMO Infant Formula Market Challenges
1.3.4 HMO Infant Formula Market Restraints
1.3.5 Impact of U.S. Tariffs
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global HMO Infant Formula Players Revenue Ranking (2025)
2.2 Global HMO Infant Formula Revenue by Company (2021–2026)
2.3 Global HMO Infant Formula Sales Volume Ranking of Players (2025)
2.4 Global HMO Infant Formula Sales Volume by Company (2021–2026)
2.5 Global HMO Infant Formula Average Price by Company (2021–2026)
2.6 Key Manufacturers HMO Infant Formula Manufacturing Base and Headquarters
2.7 Key Manufacturers HMO Infant Formula Product Offerings
2.8 Key Manufacturers Start of Mass Production of HMO Infant Formula
2.9 HMO Infant Formula Market Competitive Analysis
2.9.1 HMO Infant Formula Market Concentration Rate (2021–2026)
2.9.2 Global 5 and 10 Largest Manufacturers by HMO Infant Formula Revenue in 2025
2.9.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on HMO Infant Formula revenue, 2025
2.10 Mergers & Acquisitions and Expansion
3 Segmentation HMO Infant Formula Market Classification
3.1 Introduction by Type
3.1.1 2'-Fucosyllactose (2'-FL)
3.1.2 Others
3.1.3 Global HMO Infant Formula Sales Value by Type
3.1.3.1 Global HMO Infant Formula Sales Value by Type (2021 vs 2025 vs 2032)
3.1.3.2 Global HMO Infant Formula Sales Value, by Type (2021–2032)
3.1.3.3 Global HMO Infant Formula Sales Value, by Type (%), 2021–2032
3.1.4 Global HMO Infant Formula Sales Volume by Type
3.1.4.1 Global HMO Infant Formula Sales Volume by Type (2021 vs 2025 vs 2032)
3.1.4.2 Global HMO Infant Formula Sales Volume, by Type (2021–2032)
3.1.4.3 Global HMO Infant Formula Sales Volume, by Type (%), 2021–2032
3.1.5 Global HMO Infant Formula Average Price by Type (2021–2032)
4 Segmentation by Sales Channel
4.1 Introduction by Sales Channel
4.1.1 Online Channel
4.1.2 Specialty Store
4.1.3 Supermarket
4.1.4 Others
4.2 Global HMO Infant Formula Sales Value by Sales Channel
4.2.1 Global HMO Infant Formula Sales Value by Sales Channel (2021 vs 2025 vs 2032)
4.2.2 Global HMO Infant Formula Sales Value, by Sales Channel (2021–2032)
4.2.3 Global HMO Infant Formula Sales Value, by Sales Channel (%), 2021–2032
4.3 Global HMO Infant Formula Sales Volume by Sales Channel
4.3.1 Global HMO Infant Formula Sales Volume by Sales Channel (2021 vs 2025 vs 2032)
4.3.2 Global HMO Infant Formula Sales Volume, by Sales Channel (2021–2032)
4.3.3 Global HMO Infant Formula Sales Volume, by Sales Channel (%), 2021–2032
4.4 Global HMO Infant Formula Average Price by Sales Channel (2021–2032)
5 Segmentation by Region
5.1 Global HMO Infant Formula Sales Value by Region
5.1.1 Global HMO Infant Formula Sales Value by Region: 2021 vs 2025 vs 2032
5.1.2 Global HMO Infant Formula Sales Value by Region (2021–2026)
5.1.3 Global HMO Infant Formula Sales Value by Region (2027–2032)
5.1.4 Global HMO Infant Formula Sales Value by Region (%), 2021–2032
5.2 Global HMO Infant Formula Sales Volume by Region
5.2.1 Global HMO Infant Formula Sales Volume by Region: 2021 vs 2025 vs 2032
5.2.2 Global HMO Infant Formula Sales Volume by Region (2021–2026)
5.2.3 Global HMO Infant Formula Sales Volume by Region (2027–2032)
5.2.4 Global HMO Infant Formula Sales Volume by Region (%), 2021–2032
5.3 Global HMO Infant Formula Average Price by Region (2021–2032)
5.4 North America
5.4.1 North America HMO Infant Formula Sales Value, 2021–2032
5.4.2 North America HMO Infant Formula Sales Value by Country (%), 2025 vs 2032
5.5 Europe
5.5.1 Europe HMO Infant Formula Sales Value, 2021–2032
5.5.2 Europe HMO Infant Formula Sales Value by Country (%), 2025 vs 2032
5.6 Asia Pacific
5.6.1 Asia Pacific HMO Infant Formula Sales Value, 2021–2032
5.6.2 Asia Pacific HMO Infant Formula Sales Value by Region (%), 2025 vs 2032
5.7 South America
5.7.1 South America HMO Infant Formula Sales Value, 2021–2032
5.7.2 South America HMO Infant Formula Sales Value by Country (%), 2025 vs 2032
5.8 Middle East & Africa
5.8.1 Middle East & Africa HMO Infant Formula Sales Value, 2021–2032
5.8.2 Middle East & Africa HMO Infant Formula Sales Value by Country (%), 2025 vs 2032
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions HMO Infant Formula Sales Value Growth Trends, 2021 vs 2025 vs 2032
6.2 Key Countries/Regions HMO Infant Formula Sales Value and Sales Volume
6.2.1 Key Countries/Regions HMO Infant Formula Sales Value, 2021–2032
6.2.2 Key Countries/Regions HMO Infant Formula Sales Volume, 2021–2032
6.3 United States
6.3.1 United States HMO Infant Formula Sales Value, 2021–2032
6.3.2 United States HMO Infant Formula Sales Value by Type (%), 2025 vs 2032
6.3.3 United States HMO Infant Formula Sales Value by Sales Channel, 2025 vs 2032
6.4 Europe
6.4.1 Europe HMO Infant Formula Sales Value, 2021–2032
6.4.2 Europe HMO Infant Formula Sales Value by Type (%), 2025 vs 2032
6.4.3 Europe HMO Infant Formula Sales Value by Sales Channel, 2025 vs 2032
6.5 China
6.5.1 China HMO Infant Formula Sales Value, 2021–2032
6.5.2 China HMO Infant Formula Sales Value by Type (%), 2025 vs 2032
6.5.3 China HMO Infant Formula Sales Value by Sales Channel, 2025 vs 2032
6.6 Japan
6.6.1 Japan HMO Infant Formula Sales Value, 2021–2032
6.6.2 Japan HMO Infant Formula Sales Value by Type (%), 2025 vs 2032
6.6.3 Japan HMO Infant Formula Sales Value by Sales Channel, 2025 vs 2032
6.7 South Korea
6.7.1 South Korea HMO Infant Formula Sales Value, 2021–2032
6.7.2 South Korea HMO Infant Formula Sales Value by Type (%), 2025 vs 2032
6.7.3 South Korea HMO Infant Formula Sales Value by Sales Channel, 2025 vs 2032
6.8 Southeast Asia
6.8.1 Southeast Asia HMO Infant Formula Sales Value, 2021–2032
6.8.2 Southeast Asia HMO Infant Formula Sales Value by Type (%), 2025 vs 2032
6.8.3 Southeast Asia HMO Infant Formula Sales Value by Sales Channel, 2025 vs 2032
6.9 India
6.9.1 India HMO Infant Formula Sales Value, 2021–2032
6.9.2 India HMO Infant Formula Sales Value by Type (%), 2025 vs 2032
6.9.3 India HMO Infant Formula Sales Value by Sales Channel, 2025 vs 2032
7 Company Profiles
7.1 Abbott
7.1.1 Abbott Company Information
7.1.2 Abbott Introduction and Business Overview
7.1.3 Abbott HMO Infant Formula Sales, Revenue, Price and Gross Margin (2021–2026)
7.1.4 Abbott HMO Infant Formula Product Offerings
7.1.5 Abbott Recent Developments
7.2 Mead Johnson（Reckitt）
7.2.1 Mead Johnson（Reckitt） Company Information
7.2.2 Mead Johnson（Reckitt） Introduction and Business Overview
7.2.3 Mead Johnson（Reckitt） HMO Infant Formula Sales, Revenue, Price and Gross Margin (2021–2026)
7.2.4 Mead Johnson（Reckitt） HMO Infant Formula Product Offerings
7.2.5 Mead Johnson（Reckitt） Recent Developments
7.3 Nestlé（Wyeth Nutrition）
7.3.1 Nestlé（Wyeth Nutrition） Company Information
7.3.2 Nestlé（Wyeth Nutrition） Introduction and Business Overview
7.3.3 Nestlé（Wyeth Nutrition） HMO Infant Formula Sales, Revenue, Price and Gross Margin (2021–2026)
7.3.4 Nestlé（Wyeth Nutrition） HMO Infant Formula Product Offerings
7.3.5 Nestlé（Wyeth Nutrition） Recent Developments
7.4 Danone (Aptamil)
7.4.1 Danone (Aptamil) Company Information
7.4.2 Danone (Aptamil) Introduction and Business Overview
7.4.3 Danone (Aptamil) HMO Infant Formula Sales, Revenue, Price and Gross Margin (2021–2026)
7.4.4 Danone (Aptamil) HMO Infant Formula Product Offerings
7.4.5 Danone (Aptamil) Recent Developments
7.5 FrieslandCampina (Friso)
7.5.1 FrieslandCampina (Friso) Company Information
7.5.2 FrieslandCampina (Friso) Introduction and Business Overview
7.5.3 FrieslandCampina (Friso) HMO Infant Formula Sales, Revenue, Price and Gross Margin (2021–2026)
7.5.4 FrieslandCampina (Friso) HMO Infant Formula Product Offerings
7.5.5 FrieslandCampina (Friso) Recent Developments
7.6 Biostime
7.6.1 Biostime Company Information
7.6.2 Biostime Introduction and Business Overview
7.6.3 Biostime HMO Infant Formula Sales, Revenue, Price and Gross Margin (2021–2026)
7.6.4 Biostime HMO Infant Formula Product Offerings
7.6.5 Biostime Recent Developments
7.7 Yili Group (Ausnutria Dairy)
7.7.1 Yili Group (Ausnutria Dairy) Company Information
7.7.2 Yili Group (Ausnutria Dairy) Introduction and Business Overview
7.7.3 Yili Group (Ausnutria Dairy) HMO Infant Formula Sales, Revenue, Price and Gross Margin (2021–2026)
7.7.4 Yili Group (Ausnutria Dairy) HMO Infant Formula Product Offerings
7.7.5 Yili Group (Ausnutria Dairy) Recent Developments
8 Industry Chain Analysis
8.1 HMO Infant Formula Industrial Chain
8.2 HMO Infant Formula Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Key Suppliers of Raw Materials
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customer Analysis)
8.5 Sales Model and Sales Channelss
8.5.1 HMO Infant Formula Sales Model
8.5.2 Sales Channels
8.5.3 HMO Infant Formula Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. HMO Infant Formula Market Trends
Table 2. HMO Infant Formula Market Drivers & Opportunities
Table 3. HMO Infant Formula Market Challenges
Table 4. HMO Infant Formula Market Restraints
List of Figures
Figure 1. HMO Infant Formula Product Picture
Figure 2. Global HMO Infant Formula Sales Value, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Global HMO Infant Formula Sales Value (US$ Million), 2021–2032
Figure 4. Global HMO Infant Formula Sales Volume (Tons), 2021–2032
Figure 5. Global HMO Infant Formula Sales Price (US$/kg), 2021–2032
Figure 6. HMO Infant Formula Report Years Considered
Figure 7. Global HMO Infant Formula Players Revenue Ranking (US$ Million), 2025
Figure 8. Global HMO Infant Formula Sales Volume Ranking of Players (Tons), 2025
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by HMO Infant Formula Revenue in 2025
Figure 10. HMO Infant Formula Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 11. 2'-Fucosyllactose (2'-FL) Picture
Figure 12. Others Picture
Figure 13. Global HMO Infant Formula Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global HMO Infant Formula Sales Value Market Share by Type, 2025 & 2032
Figure 15. Global HMO Infant Formula Sales Volume by Type (Tons), 2021 vs 2025 vs 2032
Figure 16. Global HMO Infant Formula Sales Volume Market Share by Type, 2025 & 2032
Figure 17. Global HMO Infant Formula Price by Type (US$/kg), 2021–2032
Figure 18. Product Picture of Online Channel
Figure 19. Product Picture of Specialty Store
Figure 20. Product Picture of Supermarket
Figure 21. Product Picture of Others
Figure 22. Global HMO Infant Formula Sales Value by Sales Channel (US$ Million), 2021 vs 2025 vs 2032
Figure 23. Global HMO Infant Formula Sales Value Market Share by Sales Channel, 2025 & 2032
Figure 24. Global HMO Infant Formula Sales Volume by Sales Channel (Tons), 2021 vs 2025 vs 2032
Figure 25. Global HMO Infant Formula Sales Volume Market Share by Sales Channel, 2025 & 2032
Figure 26. Global HMO Infant Formula Price by Sales Channel (US$/kg), 2021–2032
Figure 27. North America HMO Infant Formula Sales Value (US$ Million), 2021–2032
Figure 28. North America HMO Infant Formula Sales Value by Country (%), 2025 vs 2032
Figure 29. Europe HMO Infant Formula Sales Value (US$ Million), 2021–2032
Figure 30. Europe HMO Infant Formula Sales Value by Country (%), 2025 vs 2032
Figure 31. Asia Pacific HMO Infant Formula Sales Value (US$ Million), 2021–2032
Figure 32. Asia Pacific HMO Infant Formula Sales Value by Region (%), 2025 vs 2032
Figure 33. South America HMO Infant Formula Sales Value (US$ Million), 2021–2032
Figure 34. South America HMO Infant Formula Sales Value by Country (%), 2025 vs 2032
Figure 35. Middle East & Africa HMO Infant Formula Sales Value (US$ Million), 2021–2032
Figure 36. Middle East & Africa HMO Infant Formula Sales Value by Country (%), 2025 vs 2032
Figure 37. Key Countries/Regions HMO Infant Formula Sales Value (%), 2021–2032
Figure 38. Key Countries/Regions HMO Infant Formula Sales Volume (%), 2021–2032
Figure 39. United States HMO Infant Formula Sales Value (US$ Million), 2021–2032
Figure 40. United States HMO Infant Formula Sales Value by Type (%), 2025 vs 2032
Figure 41. United States HMO Infant Formula Sales Value by Sales Channel (%), 2025 vs 2032
Figure 42. Europe HMO Infant Formula Sales Value (US$ Million), 2021–2032
Figure 43. Europe HMO Infant Formula Sales Value by Type (%), 2025 vs 2032
Figure 44. Europe HMO Infant Formula Sales Value by Sales Channel (%), 2025 vs 2032
Figure 45. China HMO Infant Formula Sales Value (US$ Million), 2021–2032
Figure 46. China HMO Infant Formula Sales Value by Type (%), 2025 vs 2032
Figure 47. China HMO Infant Formula Sales Value by Sales Channel (%), 2025 vs 2032
Figure 48. Japan HMO Infant Formula Sales Value (US$ Million), 2021–2032
Figure 49. Japan HMO Infant Formula Sales Value by Type (%), 2025 vs 2032
Figure 50. Japan HMO Infant Formula Sales Value by Sales Channel (%), 2025 vs 2032
Figure 51. South Korea HMO Infant Formula Sales Value (US$ Million), 2021–2032
Figure 52. South Korea HMO Infant Formula Sales Value by Type (%), 2025 vs 2032
Figure 53. South Korea HMO Infant Formula Sales Value by Sales Channel (%), 2025 vs 2032
Figure 54. Southeast Asia HMO Infant Formula Sales Value (US$ Million), 2021–2032
Figure 55. Southeast Asia HMO Infant Formula Sales Value by Type (%), 2025 vs 2032
Figure 56. Southeast Asia HMO Infant Formula Sales Value by Sales Channel (%), 2025 vs 2032
Figure 57. India HMO Infant Formula Sales Value (US$ Million), 2021–2032
Figure 58. India HMO Infant Formula Sales Value by Type (%), 2025 vs 2032
Figure 59. India HMO Infant Formula Sales Value by Sales Channel (%), 2025 vs 2032
Figure 60. HMO Infant Formula Industrial Chain
Figure 61. HMO Infant Formula Manufacturing Cost Structure
Figure 62. Channels of Distribution (Direct Sales, and Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which region is expected to have the highest market share?
For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 10.8% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.
What was the global market size of HMO Infant Formula in 2026?
What was the global market size of HMO Infant Formula in 2032?
Which companies rank high in the global HMO Infant Formula market?
What is the annual compound growth rate of the global HMO Infant Formula market size from 2026 to 2032?
Related Reports
Global HMO Infant Formula Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global HMO Infant Formula market size was US$ 4236 million in 2025 and is forecast to reach a readjusted size of US$ 8615 million by 2032 with a CAGR of 10.8% during the forecast period 2026-2032.
Published Date: 2026-01-05
Pages: 77
USD 4250.00
(Single User License)
Global HMO Infant Formula Market Research Report 2026
The global HMO Infant Formula market was valued at US$ 4236 million in 2025 and is anticipated to reach US$ 8615 million by 2032, at a CAGR of 10.8% from 2026 to 2032.
Published Date: 2026-01-05
Pages: 112
USD 2900.00
(Single User License)
Global HMO Infant Formula Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global HMO Infant Formula market size was US$ 3860 million in 2024 and is forecast to a readjusted size of US$ 7850 million by 2031 with a CAGR of 10.8% during the forecast period 2025-2031.
Published Date: 2025-09-10
Pages: 78
USD 4250.00
(Single User License)
Global HMO Infant Formula Market Outlook, In‑Depth Analysis & Forecast to 2031
The global HMO Infant Formula market is projected to grow from US$ 3860 million in 2024 to US$ 7850 million by 2031, at a CAGR of 10.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-07-31
Pages: 134
USD 4900.00
(Single User License)
HMO Infant Formula- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for HMO Infant Formula was estimated to be worth US$ 3860 million in 2024 and is forecast to a readjusted size of US$ 7850 million by 2031 with a CAGR of 10.8% during the forecast period 2025-2031.
Published Date: 2025-01-19
Pages: 107
USD 3950.00
(Single User License)
Global HMO Infant Formula Market Research Report 2025
The global market for HMO Infant Formula was valued at US$ 3860 million in the year 2024 and is projected to reach a revised size of US$ 7850 million by 2031, growing at a CAGR of 10.8% during the forecast period.
Published Date: 2025-01-19
Pages: 81
USD 2900.00
(Single User License)
Global and China HMO Infant Formula Market Report & Forecast 2024-2030
Human milk oligosaccharides (HMOs) are the third most abundant component in breast milk and one of the most important components in breast milk. It is precisely because of the existence of HMOs that breastfeeding has become the gold standard for infant nutrition. The latest research shows that HMOs can effectively enhance the benefits of breastfeeding, such as strengthening the immune system and promoting healthy brain development. In addition, HMOs can promote intestinal development, improve intestinal resilience, and promote the balance of intestinal microbiota. HMO is particularly important in improving the health and nutritional needs of infants and young children. Since infant formula is mainly made from cow and goat milk, and the content of HMO in cow and goat milk is very low, adding HMO to infant formula is more in line with breast milk nutrition and can better protect the healthy growth of babies.
Published Date: 2024-06-20
Pages: 119
USD 4350.00
(Single User License)
HMO Infant Formula- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Human milk oligosaccharides (HMOs) are the third most abundant component in breast milk and one of the most important components in breast milk. It is precisely because of the existence of HMOs that breastfeeding has become the gold standard for infant nutrition. The latest research shows that HMOs can effectively enhance the benefits of breastfeeding, such as strengthening the immune system and promoting healthy brain development. In addition, HMOs can promote intestinal development, improve intestinal resilience, and promote the balance of intestinal microbiota. HMO is particularly important in improving the health and nutritional needs of infants and young children. Since infant formula is mainly made from cow and goat milk, and the content of HMO in cow and goat milk is very low, adding HMO to infant formula is more in line with breast milk nutrition and can better protect the healthy growth of babies.
Published Date: 2024-06-20
Pages: 91
USD 3950.00
(Single User License)
Global HMO Infant Formula Market Insights, Forecast to 2030
Human milk oligosaccharides (HMOs) are the third most abundant component in breast milk and one of the most important components in breast milk. It is precisely because of the existence of HMOs that breastfeeding has become the gold standard for infant nutrition. The latest research shows that HMOs can effectively enhance the benefits of breastfeeding, such as strengthening the immune system and promoting healthy brain development. In addition, HMOs can promote intestinal development, improve intestinal resilience, and promote the balance of intestinal microbiota. HMO is particularly important in improving the health and nutritional needs of infants and young children. Since infant formula is mainly made from cow and goat milk, and the content of HMO in cow and goat milk is very low, adding HMO to infant formula is more in line with breast milk nutrition and can better protect the healthy growth of babies.
Published Date: 2024-06-20
Pages: 126
USD 4900.00
(Single User License)
Global HMO Infant Formula Market Research Report 2024
Human milk oligosaccharides (HMOs) are the third most abundant component in breast milk and one of the most important components in breast milk. It is precisely because of the existence of HMOs that breastfeeding has become the gold standard for infant nutrition. The latest research shows that HMOs can effectively enhance the benefits of breastfeeding, such as strengthening the immune system and promoting healthy brain development. In addition, HMOs can promote intestinal development, improve intestinal resilience, and promote the balance of intestinal microbiota. HMO is particularly important in improving the health and nutritional needs of infants and young children. Since infant formula is mainly made from cow and goat milk, and the content of HMO in cow and goat milk is very low, adding HMO to infant formula is more in line with breast milk nutrition and can better protect the healthy growth of babies.
Published Date: 2024-06-20
Pages: 78
USD 2900.00
(Single User License)
Global HMO Infant Formula Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global HMO Infant Formula market size was US$ 4236 million in 2025 and is forecast to reach a readjusted size of US$ 8615 million by 2032 with a CAGR of 10.8% during the forecast period 2026-2032.
Published: 2026-01-05
Pages: 77
USD 4250.00 (Single User License)Global HMO Infant Formula Market Research Report 2026
The global HMO Infant Formula market was valued at US$ 4236 million in 2025 and is anticipated to reach US$ 8615 million by 2032, at a CAGR of 10.8% from 2026 to 2032.
Published: 2026-01-05
Pages: 112
USD 2900.00 (Single User License)Global HMO Infant Formula Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global HMO Infant Formula market size was US$ 3860 million in 2024 and is forecast to a readjusted size of US$ 7850 million by 2031 with a CAGR of 10.8% during the forecast period 2025-2031.
Published: 2025-09-10
Pages: 78
USD 4250.00 (Single User License)Global HMO Infant Formula Market Outlook, In‑Depth Analysis & Forecast to 2031
The global HMO Infant Formula market is projected to grow from US$ 3860 million in 2024 to US$ 7850 million by 2031, at a CAGR of 10.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-07-31
Pages: 134
USD 4900.00 (Single User License)HMO Infant Formula- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for HMO Infant Formula was estimated to be worth US$ 3860 million in 2024 and is forecast to a readjusted size of US$ 7850 million by 2031 with a CAGR of 10.8% during the forecast period 2025-2031.
Published: 2025-01-19
Pages: 107
USD 3950.00 (Single User License)Global HMO Infant Formula Market Research Report 2025
The global market for HMO Infant Formula was valued at US$ 3860 million in the year 2024 and is projected to reach a revised size of US$ 7850 million by 2031, growing at a CAGR of 10.8% during the forecast period.
Published: 2025-01-19
Pages: 81
USD 2900.00 (Single User License)Global and China HMO Infant Formula Market Report & Forecast 2024-2030
Human milk oligosaccharides (HMOs) are the third most abundant component in breast milk and one of the most important components in breast milk. It is precisely because of the existence of HMOs that breastfeeding has become the gold standard for infant nutrition. The latest research shows that HMOs can effectively enhance the benefits of breastfeeding, such as strengthening the immune system and promoting healthy brain development. In addition, HMOs can promote intestinal development, improve intestinal resilience, and promote the balance of intestinal microbiota. HMO is particularly important in improving the health and nutritional needs of infants and young children. Since infant formula is mainly made from cow and goat milk, and the content of HMO in cow and goat milk is very low, adding HMO to infant formula is more in line with breast milk nutrition and can better protect the healthy growth of babies.
Published: 2024-06-20
Pages: 119
USD 4350.00 (Single User License)HMO Infant Formula- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Human milk oligosaccharides (HMOs) are the third most abundant component in breast milk and one of the most important components in breast milk. It is precisely because of the existence of HMOs that breastfeeding has become the gold standard for infant nutrition. The latest research shows that HMOs can effectively enhance the benefits of breastfeeding, such as strengthening the immune system and promoting healthy brain development. In addition, HMOs can promote intestinal development, improve intestinal resilience, and promote the balance of intestinal microbiota. HMO is particularly important in improving the health and nutritional needs of infants and young children. Since infant formula is mainly made from cow and goat milk, and the content of HMO in cow and goat milk is very low, adding HMO to infant formula is more in line with breast milk nutrition and can better protect the healthy growth of babies.
Published: 2024-06-20
Pages: 91
USD 3950.00 (Single User License)Global HMO Infant Formula Market Insights, Forecast to 2030
Human milk oligosaccharides (HMOs) are the third most abundant component in breast milk and one of the most important components in breast milk. It is precisely because of the existence of HMOs that breastfeeding has become the gold standard for infant nutrition. The latest research shows that HMOs can effectively enhance the benefits of breastfeeding, such as strengthening the immune system and promoting healthy brain development. In addition, HMOs can promote intestinal development, improve intestinal resilience, and promote the balance of intestinal microbiota. HMO is particularly important in improving the health and nutritional needs of infants and young children. Since infant formula is mainly made from cow and goat milk, and the content of HMO in cow and goat milk is very low, adding HMO to infant formula is more in line with breast milk nutrition and can better protect the healthy growth of babies.
Published: 2024-06-20
Pages: 126
USD 4900.00 (Single User License)Global HMO Infant Formula Market Research Report 2024
Human milk oligosaccharides (HMOs) are the third most abundant component in breast milk and one of the most important components in breast milk. It is precisely because of the existence of HMOs that breastfeeding has become the gold standard for infant nutrition. The latest research shows that HMOs can effectively enhance the benefits of breastfeeding, such as strengthening the immune system and promoting healthy brain development. In addition, HMOs can promote intestinal development, improve intestinal resilience, and promote the balance of intestinal microbiota. HMO is particularly important in improving the health and nutritional needs of infants and young children. Since infant formula is mainly made from cow and goat milk, and the content of HMO in cow and goat milk is very low, adding HMO to infant formula is more in line with breast milk nutrition and can better protect the healthy growth of babies.
Published: 2024-06-20
Pages: 78
USD 2900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 3950.00
USD 5925.00
USD 7900.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now